Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis

Abstract

Monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B-cell disorders associated with an increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (RZV) in these patients. Individuals with MBL/untreated CLL and Bruton tyrosine kinase inhibitor (BTKi)-treated CLL patients were given two doses of RZV separated by 2 months. Responses assessed at 3 and 12 months from the first dose of RZV by an anti-glycoprotein E ELISA antibody assay and by dual-color Interferon-γ and Interleukin-2FLUOROSPOT assays were compared to historic controls matched by age and sex. About 62 patients (37 MBL/untreated CLL and 25 BTKi-treated CLL)were enrolled with a median age of 68 years at vaccination. An antibody response at 3 months was seen in 45% of participants, which was significantly lower compared to historic controls (63%, p = .03). The antibody response did not significantly differ between MBL/untreated CLL and BTKi-treated CLL (51% vs. 36%, respectively, p = .23). The CD4+ T-cell response to vaccination was significantly lower in study participants compared to controls (54% vs. 96%, p < .001), mainly due to lower responses among BTKi-treated patients compared to untreated MBL/CLL (32% vs. 73%, p = .008).Overall, only 29% of participants achieved combined antibody and cellular responses to RZV. Among participants with response assessment at 12 months (n = 47), 24% had antibody titers below the response threshold. Hypogammaglobulinemia and BTKi therapy were associated with reduced T-cell responses in a univariate analysis. Strategies to improve vaccine response to RZV among MBL/CLL patients are needed.Adriana Weinberg and Sameer A. Parikh contributed equally.

Varicella zoster virus reactivation following COVID‐19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross‐sectional Chinese study of 318 cases

“…CMI plays a critical role in the protection of VZV reactivation. 22 Studies have reported COVID-19 infection can damage the function of CD4+ T cells, natural killer cells, and CD8+ T cells, which may potentially lead to HZ reactivation. 23 vaccines, and they demonstrated that mRNA induced higher neutralizing antibodies than inactivated vaccine.…”

Current Methods for the Detection of Antibodies of Varicella-Zoster Virus: A Review

“…In general, the gp-ELISA has high sensitivity and specificity, and a high consistency with FAMA, and is thus considered to be the most likely alternative to FAMA [ 54 ]. In addition, GSK also developed an in-house ELISA to detect VZV gE antibody (gE-ELISA) and applied it to evaluating the immunogenicity of a herpes zoster subunit vaccine Shingrix [ 55 ].…”

Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2

“…Impaired seroconversion was also reported after 13 and 23 valent Pneumococcus vaccine (PCV13 and PPV23) [ [58] , [59] , [60] ]. On the contrary, recombinant Varicella Zoster vaccine (rVZV) was associated with higher seroconversion rates (41 to 75%), although with lower responses in those receiving BTKi for longer period [ [61] , [62] , [63] , [64] ].…”